65,437 trials
Generalized Anxiety Disorder (GAD)
Primary: Change From Baseline in Hamilton Anxiety Rating Scale (HAM-A) Total Score at Visit 7 (Day 42) — -9.01; -8.93 Score on scale
Kawasaki Disease Refractory to Initial Therapy With Intravenous Immunoglobulin
Primary: Defervescence Rate Within 48 Hours After the Start of the Study Drug Administration — 75.0; 33.3 percentage of patients
Plaque Psoriasis
Primary: Hypothalamic-Pituitary-Adrenal (HPA) Axis Response — 19; 6 Participants
Endometriosis, Pain
Primary: Change From Baseline in the Monthly Mean Dysmenorrhea Score During the Double-blind Treatment Phase — -0.24; -0.49; -0.37; -1.13 units on a scale — p=0.0262
Celiac Disease
Primary: Number of Subjects With Changes of Villous Architecture Undergoing OFDI Imaging — 6 Participants
Adult Hepatocellular Carcinoma · Localized Resectable Adult Liver Carcinoma
Primary: Fluorine-18 (18F) Fluoromethylcholine (FCH) PET/CT Parameters for Assessing Hepatocellular Carcinoma (HCC): Area Under the Receiver Operating Characteristic Curve…
Adherence to HIV Treatment and Medication
Primary: Log10 HIV-1 Viral Load — 1.48; 1.82 Log10 copies/ml
Laryngeal Masks
Primary: First Attempt Success Rate — 59; 65 Participants
Surgical Site Infection · Cosmetic Appearance of Cesarean Scar · Post Operative Pain
Primary: Percentage of Patients Who Develop a Surgical Site Infection — 14; 15 Participants — p=<0.05
Obsessive Compulsive Disorder · Trichotillomania
Primary: Composite Score of Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) and National Institute of Mental Health (NIMH) — -.38; .46; -.89; -.52 z scores — p== 0.56
Presbyopia · Refractive Errors
Primary: Mean Number of Trial Lenses Needed to Fit Each Eye — 1.2; 1.4 lenses
Healthy
Primary: Performance: EEG Recordings - Impedance — 2.3 Impedance (kOhm)
Spinal Cord Injury · Bone Loss · Osteoporosis
Primary: BMD of Total Hip by DXA — 1.32 Percent change
Parkinson's Disease
Primary: MDS-UPDRS Motor III Score — -4.8; -4.9; 1.8 change in MDS- UPDRS III score
Melanoma
Primary: Percentage of Participants With Relapse-free Survival (RFS) Events — 163; 247; 3; 1 Participants